Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer

By /

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.

Scroll to Top